HI
TEVA icon

Harrington Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Harrington Investments’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$3K – 156
2018
Q1 		$3K Buy
+200
New +$3.9K ﹤0.01% 153

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Harrington Investments's TEVA Position: Q2 2018 in Review

Harrington Investments sold out of Teva Pharmaceuticals (TEVA) in Q2 2018, closing a stake of 200 shares — an estimated $3K sold.

Harrington Investments first reported a position in TEVA in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 540 funds tracked by Wall St. Rank hold TEVA as of Q2 2018.

  • Harrington Investments reported no remaining Teva Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Harrington Investments sold 200 Teva Pharmaceuticals shares in Q2 2018, an estimated $3K.
  • Harrington Investments first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Harrington Investments's Teva Pharmaceuticals position peaked at $3K in Q1 2018.
  • 540 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2018.

Based on Harrington Investments's 13F filing for Q2 2018, filed 14 Sep 2018.